Your search returned 9 results.

Sort
Results
1.
Effects of weight loss, weight cycling, and weight loss maintenance on diabetes incidence and change in cardiometabolic traits in the Diabetes Prevention Program. MedStar authors:
  • Aroda, Vanita R
PMID:
  • 25024396
Year: 2014
Citation:
  • Diabetes Care. 37(10):2738-45, 2014 Oct.
Institution:
  • MedStar Health Research Institute
Medline publication type:
  • Journal Article
  • Observational Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
Form of publication:
  • Journal Article
All authors:
  • Aroda VR, Bray GA, Delahanty LM, Diabetes Prevention Program Research Group, Florez JC, Franks PW, Jablonski KA, Kahn SE, Pan Q, Perreault L, Watson KE
2.
Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial. MedStar authors:
  • Aroda, Vanita R
PMID:
  • 31359368
Year: 2019
Citation:
  • Advances in Therapy. 36(9):2310-2326, 2019 09.
Institution:
  • MedStar Health Research Institute
Medline publication type:
  • Journal Article
Form of publication:
  • Journal Article
All authors:
  • Aroda VR, Bailey TS, Blonde L, Chao J, Dex TA, Frias JP, Meneghini LF, Roberts M
3.
Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial. MedStar authors:
  • Aroda, Vanita R
PMID:
  • 27284114
Year: 2016
Citation:
  • Diabetes Care. 39(9):1579-86, 2016 Sep
Institution:
  • MedStar Health Research Institute
Medline publication type:
  • Journal Article
Form of publication:
  • Journal Article
All authors:
  • Aroda VR, Diamant M, Fonseca V, LixiLan PoC Study Group, Perfetti R, Rosenstock J, Silvestre L, Souhami E, Zhou T
4.
Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) versus insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial. MedStar authors:
  • Aroda, Vanita R
PMID:
  • 28386990
Year: 2017
Citation:
  • Diabetes, Obesity & Metabolism. 19(10):1408-1415, 2017 Oct.
Institution:
  • MedStar Health Research Institute
Medline publication type:
  • Journal Article
Form of publication:
  • Journal Article
All authors:
  • Aroda VR, Bergenstal RM, Bonadonna RC, Kapitza C, LixiLan-L trial investigators, Niemoeller E, Puig-Domingo M, Souhami E, Stager W, Wysham C, Yu C
5.
Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double-blind randomized controlled trial (BEGIN: ADD TO GLP-1 Study).[Erratum appears in Diabetes Obes Metab. 2016 Sep;18(9):952; PMID: 27546838] MedStar authors:
  • Aroda, Vanita R
PMID:
  • 26990378
Year: 2016
Citation:
  • Diabetes, Obesity & Metabolism. 18(7):663-70, 2016 Jul
Institution:
  • MedStar Health Research Institute
Medline publication type:
  • Journal Article
Form of publication:
  • Journal Article
All authors:
  • Andersen TH, Aroda VR, Bailey TS, Cariou B, Kumar S, Leiter LA, Philis-Tsimikas A, Raskin P, Zacho J
6.
Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. MedStar authors:
  • Aroda, Vanita R
PMID:
  • 27650977
Year: 2016
Citation:
  • Diabetes Care. 39(11):1972-1980, 2016 Nov
Institution:
  • MedStar Health Research Institute
Medline publication type:
  • Journal Article
Form of publication:
  • Journal Article
All authors:
  • Aroda VR, Bellido D, Bergenstal RM, Gonzalez-Galvez G, Guo H, LixiLan-L Trial Investigators, Niemoeller E, Rosenstock J, Souhami E, Takami A, Unger J, Wysham C
7.
Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. MedStar authors:
  • Aroda, Vanita R
PMID:
  • 29246950
Year: 2018
Citation:
  • Diabetes Care. 41(2):258-266, 2018 02.
Institution:
  • MedStar Health Research Institute
Medline publication type:
  • Journal Article
Form of publication:
  • Journal Article
All authors:
  • Ahmann AJ, Annett MP, Aroda VR, Capehorn M, Charpentier G, Dotta F, Henkel E, Holst AG, Lingvay I
8.
Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body Weight. MedStar authors:
  • Aroda, Vanita R
PMID:
  • 32139384
Year: 2020
Citation:
  • Diabetes Care. 43(5):940-947, 2020 05.
Institution:
  • MedStar Health Research Institute
Medline publication type:
  • Journal Article
Form of publication:
  • Journal Article
All authors:
  • Aroda VR, Butera NM, Camp AW, Cherrington A, Craig J, Fortmann SP, GRADE Research Group, Hollander PA, Krakoff J, Perez M, Phillips LS, Rasouli N, Sivitz WI, Tan MH, Tiktin M, Wexler DJ, Younes N
9.
Cross-sectional evaluation of noninvasively detected skin intrinsic fluorescence and mean hemoglobin a1c in type 1 diabetes. MedStar authors:
  • Aroda, Vanita R
  • Fernandez, Stephen J
  • Ratner, Robert E
PMID:
  • 23305087
Year: 2013
Citation:
  • Diabetes Technology & Therapeutics. 15(2):117-23, 2013 Feb.
Institution:
  • MedStar Health Research Institute
  • MedStar Heart & Vascular Institute
Medline publication type:
  • Journal Article
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
Form of publication:
  • Journal Article
All authors:
  • Aroda VR, Conway BN, Fernandez SJ, Matter NI, Maynard JD, Orchard TJ, Ratner RE
Pages

Powered by Koha